Literature DB >> 24846705

Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy.

Thomas A Aloia1, Giuseppe Zimmitti, Claudius Conrad, Vijaya Gottumukalla, Scott Kopetz, Jean-Nicolas Vauthey.   

Abstract

BACKGROUND: After cancer surgery, complications, and disability prevent some patients from receiving subsequent treatments. Given that an inability to complete all intended cancer therapies might negate the oncologic benefits of surgical therapy, strategies to improve return to intended oncologic treatment (RIOT), including minimally invasive surgery (MIS), are being investigated.
METHODS: This project was designed to evaluate liver tumor patients to determine the RIOT rate, risk factors for inability to RIOT, and its impact on survivals. Outcomes for a homogenous cohort of 223 patients who underwent open-approach surgery for metachronous colorectal liver metastases and a group of 27 liver tumor patients treated with MIS hepatectomy were examined.
RESULTS: Of the 223 open-approach patients, 167 were offered postoperative therapy, yielding a RIOT rate of 75%. The remaining 56 (25%) patients were unable to receive further treatment due to surgical complications (n = 29 pts) or poor performance status (n = 27 pts). Risk factors associated with inability to RIOT were hypertension (OR 2.2, P = 0.025), multiple preoperative chemotherapy regimens (OR 5.9, P = 0.039), and postoperative complications (OR 2.0, P = 0.039). Inability to RIOT correlated with shorter disease-free and overall survivals (P < 0.001, HR = 2.16; and P = 0.005, HR = 2.07, respectively). In contrast to the open surgery group, 100% of MIS patients who were intended to initiate postoperative therapy did so (P = 0.038) within a shorter median time interval (MIS: 15 days vs. open: 42 days; P < 0.001).
CONCLUSIONS: The relationship between RIOT and long-term oncologic outcomes suggests that RIOT rates for both open- and MIS-approach cancer surgery should routinely be reported as a quality indicator.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  adjuvant therapy; colorectal liver metastases; minimally invasive surgery; outcomes; surgical oncology

Mesh:

Substances:

Year:  2014        PMID: 24846705      PMCID: PMC5527828          DOI: 10.1002/jso.23626

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  36 in total

1.  Modified Makuuchi incision for foregut procedures.

Authors:  Sharon B Chang; Martin Palavecino; Curtis J Wray; Yoji Kishi; Peter W T Pisters; Jean-Nicolas Vauthey
Journal:  Arch Surg       Date:  2010-03

2.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

3.  Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases.

Authors:  Michael D'Angelica; Peter Kornprat; Mithat Gonen; Ronald P DeMatteo; Yuman Fong; Leslie H Blumgart; William R Jarnagin
Journal:  Ann Surg Oncol       Date:  2010-11-02       Impact factor: 5.344

4.  Trends in long-term survival following liver resection for hepatic colorectal metastases.

Authors:  Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

5.  Liver resection for colorectal metastases.

Authors:  Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

6.  Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver.

Authors:  M J O'Connell; M A Adson; A J Schutt; J Rubin; C G Moertel; D M Ilstrup
Journal:  Mayo Clin Proc       Date:  1985-08       Impact factor: 7.616

7.  Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.

Authors:  Thomas Aloia; Mylène Sebagh; Marylène Plasse; Vincent Karam; Francis Lévi; Sylvie Giacchetti; Daniel Azoulay; Henri Bismuth; Denis Castaing; René Adam
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  Greater complexity of liver surgery is not associated with an increased incidence of liver-related complications except for bile leak: an experience with 2,628 consecutive resections.

Authors:  Giuseppe Zimmitti; Robert E Roses; Andreas Andreou; Junichi Shindoh; Steven A Curley; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  J Gastrointest Surg       Date:  2012-09-07       Impact factor: 3.452

9.  Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer.

Authors:  Ryan P Merkow; Karl Y Bilimoria; James S Tomlinson; Jennifer L Paruch; Jason B Fleming; Mark S Talamonti; Clifford Y Ko; David J Bentrem
Journal:  Ann Surg       Date:  2014-08       Impact factor: 12.969

10.  Predictors of survival after hepatic resection among patients with colorectal liver metastasis.

Authors:  X Wang; D L Hershman; J A Abrams; D Feingold; V R Grann; J S Jacobson; A I Neugut
Journal:  Br J Cancer       Date:  2007-12-11       Impact factor: 7.640

View more
  34 in total

1.  Detours on the Road to Recovery: What Factors Delay Readiness to Return to Intended Oncologic Therapy (RIOT) After Liver Resection for Malignancy?

Authors:  Heather A Lillemoe; Rebecca K Marcus; Bradford J Kim; Nisha Narula; Catherine H Davis; Thomas A Aloia
Journal:  J Gastrointest Surg       Date:  2019-02-26       Impact factor: 3.452

2.  Determining the Safety and Efficacy of Enhanced Recovery Protocols in Major Oncologic Surgery: An Institutional NSQIP Analysis.

Authors:  Rebecca K Marcus; Heather A Lillemoe; David C Rice; Gabriel Mena; Brian K Bednarski; Barbra B Speer; Pedro T Ramirez; Javier D Lasala; Neema Navai; Wendell H Williams; Bradford J Kim; Rachel K Voss; Vijaya N Gottumukkala; Thomas A Aloia
Journal:  Ann Surg Oncol       Date:  2019-01-09       Impact factor: 5.344

3.  The Impact of Delays to Definitive Surgical Care on Survival in Colorectal Cancer Patients.

Authors:  Maude Trepanier; Tiffany Paradis; Araz Kouyoumdjian; Teodora Dumitra; Patrick Charlebois; Barry S Stein; A Sender Liberman; Kevin Schwartzman; Franco Carli; Gerald M Fried; Liane S Feldman; Lawrence Lee
Journal:  J Gastrointest Surg       Date:  2019-07-31       Impact factor: 3.452

4.  Improved Compliance With Anesthesia Quality Measures After Implementation of Automated Monthly Feedback.

Authors:  Patrick J McCormick; Cindy Yeoh; Raquel M Vicario-Feliciano; Kaitlin Ervin; Kay See Tan; Gloria Yang; Meghana Mehta; Luis Tollinche
Journal:  J Oncol Pract       Date:  2019-05-20       Impact factor: 3.840

Review 5.  Public reporting and transparency: a primer on public outcomes reporting.

Authors:  John R Romanelli; Pascal R Fuchshuber; Jonah James Stulberg; Rebecca Brewer Kowalski; Prashant Sinha; Thomas A Aloia; Rocco Orlando
Journal:  Surg Endosc       Date:  2019-06-03       Impact factor: 4.584

Review 6.  The impact of anaesthetic technique upon outcome in oncological surgery.

Authors:  M T Evans; T Wigmore; L J S Kelliher
Journal:  BJA Educ       Date:  2018-11-16

7.  Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery: ERAS for Patients Undergoing Cytoreductive Surgery with or Without HIPEC.

Authors:  Ankit Dhiman; Emily Fenton; Jeffrey Whitridge; Jennifer Belanski; Whitney Petersen; Sarah Macaraeg; Govind Rangrass; Ardaman Shergill; Dejan Micic; Oliver S Eng; Kiran Turaga
Journal:  Ann Surg Oncol       Date:  2021-05-05       Impact factor: 5.344

8.  Patient-Reported Symptom Interference as a Measure of Postsurgery Functional Recovery in Lung Cancer.

Authors:  Qiuling Shi; Xin Shelley Wang; Ara A Vaporciyan; David C Rice; Keyuri U Popat; Charles S Cleeland
Journal:  J Pain Symptom Manage       Date:  2016-08-10       Impact factor: 3.612

9.  Urgent Management of Obstructing Colorectal Cancer: Divert, Stent, or Resect?

Authors:  Songphol Malakorn; Sharon L Stein; Jeffrey H Lee; Y Nancy You
Journal:  J Gastrointest Surg       Date:  2018-10-03       Impact factor: 3.452

10.  Completion of adjuvant therapy in patients with resected pancreatic cancer.

Authors:  Danielle K DePeralta; Takuya Ogami; Jun-Min Zhou; Michael J Schell; Benjamin D Powers; Pamela J Hodul; Mokenge P Malafa; Jason B Fleming
Journal:  HPB (Oxford)       Date:  2019-09-25       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.